Scrip is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

Brought to you by

Insys Therapeutics goes public on second try; nets $34.2mm

Executive Summary

After filing to go public in March 2011, Insys Therapeutics Inc. (cancer, neurology, and gastrointestinal pharmaceuticals) has netted $34.2mm through the sale of 4.6mm common shares (including the overallotment) at $8. Last month the firm had proposed selling 4mm shares between $16-18 each, then weeks later lowered the price to $8-10. This was Insys's second IPO attempt; the first try was halted in 2007 due to market conditions.
Deal Industry
  • Biotechnology
  • Pharmaceuticals
  • Pharmaceuticals
    • Drug Delivery
Deal Status
  • Final
Deal Type
  • Financing
    • IPO

Related Companies